MYRIAD GENETICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
MYRIAD GENETICS, INC. (MYGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-02-28
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $29.20M.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $8.80M, a 2100.00% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-28 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-02-28 | ||
| 2021-12-31 | $29.20M 10-K · filed 2024-02-28 | ||
| 2020-12-31 | $500.00K 10-K · filed 2023-03-01 | ||
| 2020-06-30 | $8.80M 10-K · filed 2023-03-01 | ||
| 2019-06-30 | $400.00K 10-K · filed 2022-02-25 | ||
| 2018-06-30 | $17.00M 10-KT · filed 2021-03-16 | ||
| 2017-06-30 | $900.00K 10-K · filed 2019-08-13 | ||
| 2016-06-30 | $86.10M 10-K · filed 2018-08-24 | ||
| 2015-06-30 | $20.50M 10-K · filed 2017-08-09 | ||
| 2014-06-30 | $49.40M 10-K · filed 2016-08-10 | $49.38M 10-K · filed 2014-08-13 | |
| 2013-06-30 | $51.80M 10-K · filed 2015-08-12 | $51.78M 10-K · filed 2013-08-14 | |
| 2012-06-30 | $21.57M 10-K · filed 2014-08-13 | ||
| 2011-06-30 | $20.21M 10-K · filed 2013-08-14 | ||
| 2010-06-30 | $26.80M 10-K · filed 2012-08-15 | ||
| 2009-06-30 | $141.10M 10-K · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |